Anti-TGF beta Receptor I (phospho S165) antibody (ab112095)

Overview

  • Product nameAnti-TGF beta Receptor I (phospho S165) antibody
    See all TGF beta Receptor I primary antibodies
  • Description
    Rabbit polyclonal to TGF beta Receptor I (phospho S165)
  • Specificityab112095 detects endogenous levels of TGF beta Receptor I only when phosphorylated at serine 165.
  • Tested applicationsSuitable for: ICC/IFmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    A synthetic phosphopeptide derived from Human TGF beta Receptor I around the phosphorylation site of serine 165 (D-P-SP-L-D).

  • Positive control
    • HeLa cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab112095 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/500.

Target

  • FunctionOn ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.
  • Tissue specificityFound in all tissues examined, most abundant in placenta and least abundant in brain and heart.
  • Involvement in diseaseDefects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
    Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
    Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance.
  • Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
    Contains 1 GS domain.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AAT 5 antibody
    • AAT5 antibody
    • Activin A receptor type II like kinase 53kDa antibody
    • Activin A receptor type II like kinase, 53kD antibody
    • Activin A receptor type II like protein kinase of 53kD antibody
    • activin A receptor type II-like kinase, 53kDa antibody
    • activin A receptor type II-like protein kinase of 53kD antibody
    • Activin receptor like kinase 5 antibody
    • Activin receptor-like kinase 5 antibody
    • ACVRLK 4 antibody
    • ACVRLK4 antibody
    • ALK 5 antibody
    • ALK-5 antibody
    • ALK5 antibody
    • LDS1A antibody
    • LDS2A antibody
    • MSSE antibody
    • Serine/threonine protein kinase receptor R4 antibody
    • Serine/threonine-protein kinase receptor R4 antibody
    • SKR 4 antibody
    • SKR4 antibody
    • TbetaR I antibody
    • TbetaR-I antibody
    • TGF beta receptor type 1 antibody
    • TGF beta receptor type I antibody
    • TGF beta type I receptor antibody
    • TGF-beta receptor type I antibody
    • TGF-beta receptor type-1 antibody
    • TGF-beta type I receptor antibody
    • TGFBR 1 antibody
    • TGFBR1 antibody
    • TGFBR1 protein antibody
    • TGFR 1 antibody
    • TGFR-1 antibody
    • TGFR1 antibody
    • TGFR1_HUMAN antibody
    • Transforming growth factor beta receptor 1 antibody
    • Transforming growth factor beta receptor I (activin A receptor type II like kinase, 53kD) antibody
    • Transforming growth factor beta receptor I antibody
    • transforming growth factor, beta receptor 1 antibody
    • transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD) antibody
    • Transforming growth factor-beta receptor type I antibody
    see all

Anti-TGF beta Receptor I (phospho S165) antibody images

  • ab112095, at a 1/100 dilution, staining TGF beta Receptor I in HeLa cells by Immunofluorescence, in the absence (left) and presence (right) of the phosphopeptide.

References for Anti-TGF beta Receptor I (phospho S165) antibody (ab112095)

This product has been referenced in:
  • Rudalska R  et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138-46 (2014). Read more (PubMed: 25216638) »

See 1 Publication for this product

Product Wall

Application Western blot
Sample Human Cell lysate - whole cell (Hepatic stellate cells)
Gel Running Conditions Reduced Denaturing (8% gel)
Loading amount 20 µg
Treatment TGF-beta for 30 min or 1 hour
Specification Hepatic stellate cells
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Abcam user community

Verified customer

Submitted Mar 25 2016

Application Western blot
Loading amount 5 µg
Gel Running Conditions Reduced Denaturing (4-12% Bis-Tris)
Sample Human Cell lysate - whole cell (Lung cancer line NCI-H358)
Specification Lung cancer line NCI-H358
Treatment TGFb (10ng/ml) for 1h
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Abcam user community

Verified customer

Submitted Dec 04 2013

You can use any cell line that express endogenous TGF beta receptor 1. Please try any one of HepG2 or A549 cells, both can be used as positive control.

Es freut mich zu hören, dass Sie unser Angebot unseren ab112095 Anti-TGF beta Receptor I (phospho S165) Antikörper in WB zu testen annehmen möchten. Wie am Telefon besprochen können Sie den Gutscheincode zum Kauf eines weiteren Antikörpers einsetzen, s...

Read More

Vielen Dank für Ihren Anruf und für Ihr Interesse an unseren Produkten.

Unseres Wissens nach wurde ab112095 Anti-TGF beta Receptor I (phospho S165) antibody bisher noch nicht in WB getestet. Falls Sie dies selbst testen möchten, kann ich Ihn...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"